Drug combination for returning brain tumors in young people
Part of Cancer clinical trials.
This trial tests two drugs, axitinib and etoposide, taken by mouth to treat children and young adults with medulloblastoma or ependymoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 5 and 25 years old and weigh more than 20 kg (about 44 pounds).
- Your tumor must be medulloblastoma or ependymoma that has come back or not responded to standard therapy.
- You need to be able to swallow capsules by mouth.
- You must have a reasonable level of daily function (Karnofsky or Lansky score at least 70%).
- You must have adequate organ function, meaning your blood counts, heart, liver, and kidneys are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This study looks at how young people with certain brain tumors respond to treatment. It aims to understand why some tumors resist therapy, which may help improve future treatments.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.